Press release content from PR Newswire. The AP news staff was not involved in its creation.
Astellas Submits New Drug Application for Enfortumab Vedotin in Japan
March 11, 2021 GMT
Astellas is a pharmaceutical company dedicated to improving the health of people around the world. (PRNewsFoto/Astellas Pharma Inc.)
Astellas is a pharmaceutical company dedicated to improving the health of people around the world. (PRNewsFoto/Astellas Pharma Inc.)
TOKYO, March 11, 2021 /PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the submission of a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication. If approved, enfortumab vedotin would be the first antibody-drug conjugate (ADC) available in Japan for people living with this form of uro
Press release content from Business Wire. The AP news staff was not involved in its creation.
Allied Motion Announces Three-for-Two Stock Split and Quarterly Cash Dividend
March 10, 2021 GMT
AMHERST, N.Y. (BUSINESS WIRE) Mar 10, 2021
Allied Motion Technologies Inc. (Nasdaq: AMOT) (“Allied Motion” or the “Company”), a designer and manufacturer that sells precision and specialty controlled motion products and solutions to the global market, announced that its Board of Directors, at its meeting today, approved a three-for-two stock split of the Company’s common shares.
ADVERTISEMENT
The split will be affected by issuing one additional share of common stock for every two shares of common stock held. The additional shares will be distributed on April 30, 2021 to stockholders of record as of the close of business on April 16, 2021. Fractional share amounts resulting from the split will be paid to shareholders in cash. Allied Motion’s common stock will begin trading on a
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Flutterwave Closes USD $170m Funding
March 10, 2021 GMT
LOS ANGELES, March 10, 2021 /PRNewswire/ Flutterwave, Africa’s leading payments technology company, today announces it has secured USD $170 million from a leading group of international investors as part of a successful Series C round. The round was led by growth-equity firms Avenir Growth Capital (“Avenir”) and Tiger Global Management LLC (“Tiger Global”) with participation from new and existing investors.
Founded by entrepreneur Olugbenga Agboola in 2016, the company’s valuation is considered to be valued at more than USD $1 billion. The fundraise brings the total investment in Flutterwave to USD $225 million and is one of only a very small number of African fintech companies to have raised significant funds in a period of widespread disruption and economic uncertainty.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides .
BioXcel TherapeuticsMarch 11, 2021 GMT
New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation
TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL501; End of Phase 2 meeting with the FDA planned for Q2 2021
RELEASE trial on track to report topline results in Q1 2021
Topline results from two ongoing trials with BXCL701 in aggressive forms of prostate cancer and advanced solid tumors are expected in mid-2021